ArticleBMC ophthalmology2025
Determinants of blindness from glaucoma among patients receiving treatment: a retrospective cohort study in Enugu, Nigeria.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Time to Blindness and Associated Factors Among Glaucoma Patients Under Treatment at Governmental Hospitals in Amhara Region, Ethiopia; Application of Gamma Shared Frailty Accelerate Failure Time Model.Health science reports · 2026Article
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- High burden of blindness at initial hospitalisation with primary angle-closure glaucoma in a national multicentre study in China.BMJ open ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrreversible blindness is the natural history of untreated glaucoma; however, a significant proportion of those receiving treatment are still blind. This study sought to identify the determinant factors responsible for blindness from glaucoma among those receiving treatment.
methodThis retrospective cohort study collected data via chart review of glaucoma patients (N = 231) who attended eye clinics at a large government-owned or a privately owned health facility in Enugu, Nigeria, between October and December 2023. Visual acuity was used to determine whether the eyes met the criteria for blindness. The sociodemographic and clinical characteristics of glaucoma patients who were blind (105) and patients without blindness (126) were compared. Data analysis was performed via the statistical package for social sciences (SPSS) version 26. Binary logistic regression was used to identify determinants of blindness.
resultsThe records of a total of 231 glaucoma patients were reviewed. One hundred and five (45.5%) patients were blind in at least one eye. The mean age was 61.1 ± 13.9 years (patients without blindness) and 63.6 ± 10.6 years (blind patients). Those living in urban areas (AOR = 0.49, 95%CI = 0.24-0.99), those with no visual impairment at presentation (AOR = 0.005, 95% CI = 0.000-0.055, p < 0.0001), those with mild to moderate visual impairment (AOR = 0.125, 95% CI = 0.06-0.277, p < 0.0001), and those with presenting IOP < 22 mmHg (AOR = 0.23, 95% CI = 0.09-0.546, p = 0.001) were significantly associated with a lower risk of blindness from glaucoma. However, being non-hypertensive was associated with a higher risk of blindness from glaucoma (AOR = 2.20, 95% CI = 1.16-4.18, p = 0.043).
conclusionAmong patients receiving treatments for glaucoma, living in non-urban areas, presenting with severe visual impairments, presenting with IOP > 22 mmHg, and being non-hypertensive increased the risk of blindness. Improving access to glaucoma care in non-urban areas, increasing awareness creation on screening for early detection and patient counseling may be profitable steps towards reducing vision loss from glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.